Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 209333, held by Qilu. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 209333 (Solifenacin Succinate), held by Qilu, was first approved by FDA on May 20, 2019, with 1 approved supplement and 0 published complete response letters.
Solifenacin Succinate Tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
| Mar 17, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters